
Wuhan Oryza Biotechnology Co., Ltd. (Oryza Biotechnology) recently published the prospectus, terms of issue and preliminary solicitation notice on the official website of the Shanghai Stock Exchange, describing the commencement of the issue. This means that Oryza Biotechnology is the first company to meet and receive approval for registration, and the first company to begin work on issuing standards since the relaunch of the fifth set of standards for the Science and Technology Innovation Board. As a strategic partner of Oryza Biotechnology, Truking Technology provides solutions for the large-scale production of Oryza Biotechnology's first-ever "rice hematopoietic" product. Founded in 2006, Oryza Biotechnology is a national high-tech enterprise specialized in the research and development of botanical recombinant protein expression technology products. In July 2025, the State Food and Drug Administration approved the launch of Oryza Biotechnology, the world's first injectable recombinant human albumin (rice) drug (trade name: Aofumin), which marked a major technological breakthrough in the global biopharmaceutical production field and can be called a "miracle" in the industry. Ofumin is mainly suitable for the treatment of liver cirrhosis and hypoalbuminemia (<30 g/l). Rice seeds are used as bioreactors to produce recombinant human albumin. This technical principle received the colorful name “rice hematopoiesis.” Since 1981, there have been international attempts to produce recombinant human albumin as an alternative to plasma extraction, but no technical breakthrough has occurred.

Oryza Biotechnology The world's first “rice hematopoietic” product.
In 2006, Yang Daichang founded Oryza Biotechnology, researched the technology of using rice seeds as bioreactors to produce recombinant human albumin, and led a research and development team to solve this problem. After years of painstaking research, the team successfully implanted the human albumin gene into rice, allowing rice seeds to synthesize recombinant human albumin in large quantities. Through isolation and purification, the purity of recombinant human albumin reached more than 99.9999%. Oryza Biotechnology's success not only provides a breakthrough in "0 to 1" technology with recombinant human albumin, but also fills a gap in international large-scale manufacturing and opens new opportunities for liver disease patients worldwide.

Truking Technology and its subsidiaries are the world's first products of Oryza Biotechnology.Provide large-scale manufacturing solutions
To meet the market demand for recombinant human albumin, Oryza Biotechnology has developed a new industrialization project for recombinant human albumin, which is built around a full range of automation, information and environmental concepts. Featuring chromatography, ultrafiltration, etc. Fully automated production equipment provides complete process control from sample cleanup, CIP equipment (in-line purification) to SIP (in-line sterilization), minimizing errors and contamination risks caused by human intervention, ensuring a high degree of consistency between batches and laying a solid foundation for stable and controlled product quality. Once the project goes into production, the production capacity of Oryza Biotechnology's recombinant human albumin injection can be increased by another 12 million units. As an important partner of Oryza Biotechnology, Truking Technology is helping to build the world's first plant-derived recombinant human albumin injection production line. This industrial base project covers a total area of 148.68 acres and the total planned construction area is approximately 113,000 square meters. The project will build a fully intelligent chemical plant, integrating an administrative research and development center, pilot production and a recombinant human albumin production line. At the Oryza Biotechnology production line, Truking Technology provides a fully automated production solution, from filling and capping to product freeze drying, sterilization and padding process.
Truking Ingenuity, part of Chutian's biopharmaceuticals and life sciences industry chain, provides a complete set of total intelligent separation and purification solutions for the entire project. The solution includes dozens of sets of online liquid preparation chromatography system, ultrafiltration and other intelligent equipment. The equipment is currently undergoing intensive assembly and debugging and is expected to be delivered by the end of the year. Once the production line is operational, the production efficiency of Oryza Biotechnology's recombinant human albumin will be significantly increased, allowing it to provide services to the majority of patients more efficiently and safely.

Truking Technology and its subsidiaries are the world's first products of Oryza Biotechnology.Provide large-scale manufacturing solutions
Oryza Biotechnology has successfully achieved a breakthrough in the supply of human albumin products, providing sufficient protection for human health around the world. At the same time, Truking Technology and its subsidiaries such as Truking Ingenuity have always been committed to solving the challenges of pharmaceutical technology innovation and are committed to partnering with industry pioneers to jointly promote China's independent medical innovation and contribute to global health.




